Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting ...Middle East

Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001...

Hence then, the article about avidity biosciences provides regulatory update on aoc 1001 for myotonic dystrophy type 1 and plans to present top line data from phase 1 2 marina trial at aan annual meeting was published today ( Thursday 30/03/2023 - 02:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting )

Also on site :

• Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
• Reported tornado rips roofs off multiple homes in central Illinois
• John Legend Celebrates 47th Birthday With Family Slime Outing in New York